About Ainscorp
Established in 2008, Ainscorp Pty Ltd is an independent Australian owned company specialising in providing unique medical products that change people’s lives. Ainscorp operates in the Ostomy and Complex Wounds medical device market, an area in which both the directors and employees have decades of experience. We have products sourced from around the world, each one selected with the aim to provide people with access to the highest quality medical products to suit individual needs.
In the area of complex wound care, we source our products from Fidia Pharma S.p.A. in Italy, a range of creams and ointments made from hyaluronic acid designed to create ideal conditions for accelerated wound recovery and skin regeneration.
At Ainscorp we promote and support both patients and medical professionals through education and training products that are unique and functionally superior in their features, clinical outcomes and cost effectiveness.
With representatives throughout Australia, we are available five days a week from 9am to 5pm to provide extensive customer support both over the phone and via email.
In the area of complex wound care, we source our products from Fidia Pharma S.p.A. in Italy, a range of creams and ointments made from hyaluronic acid designed to create ideal conditions for accelerated wound recovery and skin regeneration.
At Ainscorp we promote and support both patients and medical professionals through education and training products that are unique and functionally superior in their features, clinical outcomes and cost effectiveness.
With representatives throughout Australia, we are available five days a week from 9am to 5pm to provide extensive customer support both over the phone and via email.
Our Suppliers
LEARN MORE
Innovation is a key to strengthen Fidia's portfolio and a prerequisite for the success of our customers and partners.
Continually working to identify new treatment opportunities is the framework of our commitment to patients.
High on the company's list of priorities is the study of hyaluronic acid, a molecule that at Fidia means tradition, innovation, excellence.
By modifying its chemistry, new products and innovative drug delivery systems and technology platforms are formulated that consolidate Fidia's leadership in areas such as joint healthcare, advanced wound care and aesthetic dermatology.
Fidia is continually working to identify new opportunities and develop an industry-leading pipeline of promising new treatments for specific pathologies in highly challenging areas, with products covered by international patents, that are a vital part of the company's heritage, as well as innovative formulations that will enhance their characteristics, without compromising the quality of care.
Continually working to identify new treatment opportunities is the framework of our commitment to patients.
High on the company's list of priorities is the study of hyaluronic acid, a molecule that at Fidia means tradition, innovation, excellence.
By modifying its chemistry, new products and innovative drug delivery systems and technology platforms are formulated that consolidate Fidia's leadership in areas such as joint healthcare, advanced wound care and aesthetic dermatology.
Fidia is continually working to identify new opportunities and develop an industry-leading pipeline of promising new treatments for specific pathologies in highly challenging areas, with products covered by international patents, that are a vital part of the company's heritage, as well as innovative formulations that will enhance their characteristics, without compromising the quality of care.
